Where is Big Pharma placing its bets? The upcoming ~$200B patent cliff and the stormy market conditions have significantly increased the pressure on Big Pharma to sustain pipelines while controlling costs. Most of the industry majors slashed their R&D budgets in 2022.
The era of investing in unproven bets is gone, for the foreseeable future, and only the truly innovative and commercially minded will survive.
Reviews the innovation drivers and the dramatic growth potential of this very significant market.
We believe that the “impending” recession is counterbalanced with strong economic data and once we start to peel the layers, we see a slightly different picture.
The “impending” recession is counterbalanced with strong economic data and once we start to peel the layers a different picture emerges.
“We should see a reasonably rapid recovery.”
Commercialization is key.
Reducing the costs of biologic manufacturing. (In french)
Mark Goldstone is named in 2022s Irish America Business 100.
Bloomberg Businessweek. Carol Massar and Tim Stenovec interview Youssef Sebban. May 31, 2022